Skip to main content

Schizophrenia & Psychotic Disorders

An analysis of brain scans from more than 300 patients suggests two distinct neuroanatomical subtypes of schizophrenia. Researchers published the findings online in the journal Brain.
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
Successfully treating reduced motivation, or avolition, in patients with schizophrenia has a positive effect on other negative symptoms, according to a study published online in Schizophrenia Bulletin.
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top